1UOU

Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.11 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.192 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Crystal Structure of Human Thymidine Phosphorylase in Complex with a Small Molecule Inhibitor

Norman, R.A.Barry, S.T.Bate, M.Breed, J.Colls, J.G.Ernill, R.J.Luke, R.W.A.Minshull, C.A.Mcalister, M.S.B.Mccall, E.J.Mcmicken, H.H.J.Paterson, D.S.Timms, D.Tucker, J.A.Pauptit, R.A.

(2004) Structure 12: 75

  • DOI: 10.1016/j.str.2003.11.018
  • Primary Citation of Related Structures:  
    1UOU

  • PubMed Abstract: 
  • Human thymidine phosphorylase (HTP), also known as platelet-derived endothelial cell growth factor (PD-ECGF), is overexpressed in certain solid tumors where it is linked to poor prognosis. HTP expression is utilized for certain chemotherapeutic strategies and is also thought to play a role in tumor angiogenesis ...

    Human thymidine phosphorylase (HTP), also known as platelet-derived endothelial cell growth factor (PD-ECGF), is overexpressed in certain solid tumors where it is linked to poor prognosis. HTP expression is utilized for certain chemotherapeutic strategies and is also thought to play a role in tumor angiogenesis. We determined the structure of HTP bound to the small molecule inhibitor 5-chloro-6-[1-(2-iminopyrrolidinyl) methyl] uracil hydrochloride (TPI). The inhibitor appears to mimic the substrate transition state, which may help explain the potency of this inhibitor and the catalytic mechanism of pyrimidine nucleotide phosphorylases (PYNPs). Further, we have confirmed the validity of the HTP structure as a template for structure-based drug design by predicting binding affinities for TPI and other known HTP inhibitors using in silico docking techniques. This work provides the first structural insight into the binding mode of any inhibitor to this important drug target and forms the basis for designing novel inhibitors for use in anticancer therapy.


    Organizational Affiliation

    AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
THYMIDINE PHOSPHORYLASEA474Homo sapiensMutation(s): 0 
Gene Names: TYMPECGF1
EC: 2.4.2.4
Find proteins for P19971 (Homo sapiens)
Explore P19971 
Go to UniProtKB:  P19971
NIH Common Fund Data Resources
PHAROS:  P19971
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
CMU
Query on CMU

Download Ideal Coordinates CCD File 
B [auth A]5-CHLORO-6-(1-(2-IMINOPYRROLIDINYL) METHYL) URACIL
C9 H11 Cl N4 O2
QQHMKNYGKVVGCZ-WDZFZDKYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
CMUIC50:  20   nM  BindingDB
CMUKi:  1.2999999523162842   nM  BindingDB
CMUIC50:  35   nM  BindingDB
CMUKi :  20   nM  PDBBind
CMUIC50:  23   nM  BindingDB
CMUKi:  17   nM  BindingDB
CMUKi:  20   nM  Binding MOAD
CMUIC50:  30   nM  BindingDB
CMUKi:  20   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.11 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.192 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 69.99α = 90
b = 66.09β = 106.54
c = 96.87γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
MOSFLMdata reduction
SCALAdata scaling
AMoREphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2004-01-22
    Type: Initial release
  • Version 1.1: 2011-05-08
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance